As we have been using specific anticoagulant agent named nafamostat mesylate described in above during the dialysis sessions, employing this agent showed also beneficial effects in the reduction of increased inflammatory cytokines and mediators such as IL-6, TNF-a and PAI-1 in sepsis and other critical illness (30–32). This evidence concerns the gene IL6 and Sepsis.